The Programme aims to improve and promote health in the Union to reduce the burden of communicable and non-communicable diseases by:

• protecting people from serious cross-border health threats
• improving the availability, accessibility and affordability of medicines, medical devices and other crisis-related products in the EU
• strengthening national health systems

The activities conducted under this action will focus on supporting late-stage development of medical devices, bringing them to (near-) market; improvement of existing products in terms of accessibility, affordability, or accuracy; or, in case of unmet needs, aid the creation of innovative solutions. Supported actions will need to advance beyond the current R&I status and, where applicable, must also take into account ongoing Union projects, such as under Horizon Europe, guaranteeing complementary. This will expand diagnostic capabilities to address emerging and re-emerging pathogens in the Union, by providing advanced tools to monitor and respond to outbreaks.

Updating diagnostic technologies to improve accuracy, speed, and accessibility and the optimisation of diagnostic technologies such as molecular assays and serological tests, should be supported by evidence on novel antigens or genetic sequences, including clinical testing.

The costs will be reimbursed at the funding rate fixed in the Grant Agreement (60%).
You can apply for a higher project funding rate (80%) if your project is of ‘exceptional utility’, i.e. concerns:

• actions where at least 30 % of the budget is allocated to Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average or
• actions with bodies from at least 14 Member States (or EU4H associated countries) and where at least four are from Member States (or EU4H associated countries) whose GNI per inhabitant is less than 90% of the EU average.

Grants may NOT produce a profit (i.e. surplus of revenues + EU grant over costs).
For-profit organisations must declare their revenues and, if there is a profit, we will deduct it from the final grant amount.

• Health
• Research, Technological Development and Innovation

• Associations
• Businesses
• Educational Institutions
• Large Enterprises
• Legal Entities
• NGOs
• Other Beneficiaries
• Private Bodies
• Researchers/Research Centers/Institutions
• Small and Medium Enterprises (SMEs)
• State-owned Enterprises

In order to be eligible, the applicants (beneficiaries and affiliated entities) must:

• be legal entities (public or private bodies)
• be established in one of the eligible countries, i.e.:
  • EU Member States (including overseas countries and territories (OCTs))
  • eligible non-EU countries:
    • listed EEA countries and countries associated to the EU4Health

Programme (list of participating countries)
Beneficiaries and affiliated entities must register in the Participant Register — before submitting the proposal — and will have to be validated by the Central Validation Service (REA Validation). For the validation, they will be requested to upload documents showing legal status and origin.

Other entities may participate in other consortium roles, such as associated partners, subcontractors, third parties giving in-kind contributions, etc

Consortium composition: Proposals can be submitted either by a single applicant or a consortium (no minimum requirement).

Eligible activities: Applications will only be considered eligible if their content corresponds wholly (or at least in part) to the topic description for which they are submitted.

Ministry of Health, Department of European Affairs

Ms MAKRIGIORGI Elena
Email: emakrigiorgi@moh.gov.cy

For help related to this call, please contact: HADEA-HP-CALLS@ec.europa.eu

• Funding & Tenders
• Call document